The Indian pharmaceutical industry, with current market size of USD 27.57 billion is expected to reach USD 55 billion by 2020 growing at a CAGR of 15.92 per cent.
"We have to strengthen and define the government and the private sector's role in developing the industry. The government needs to act as the provider and the private sector should deliver," industry veteran and Salus Lifesciences director Kewal Handa at 'CPhI CEO Roundtable Conference' here.
Industry leaders discussed vital issues of Make in India - ensuring country's pharma supremacy with a special focus on affordable healthcare in the urban and rural areas.
While India ranks amongst the top four pharma terms of volume of produced drugs, certain challenges continue to surround its pharma industry.
India faces issues including a time-consuming approval process, dependence on China for cheaper API sources, sub-optimal infrastructure, lack of funding avenues, and a shortage of highly skilled talent, among others, UBM India managing director, Yogesh Mudras said.
"There are quite a few issues that ail the sector and the industry should accept existing challenges and find ways to change the ecosystem," EY partner Sriram Shrinivasan said.
Speaking on the occasion, Indian Pharmaceutical Alliance secretary general D G Shah said, for 'Make in India', certain standards need to be set. It needs to take the initial steps and gain the confidence of the regulators and also understand that the industry culture and behavior are inter-linked.
The pharma industry has grown at an exponential rate and people have moved in the hierarchy, unfortunately without acquiring the requisite skill sets.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
